Regeneron to acquire gene therapy developer Decibel for $4 per share
Maksim Labkouski
Regeneron Pharmaceuticals (NASDAQ:REGN) has agreed to acquire Decibel Therapeutics (NASDAQ:DBTX), a micro-cap biotech focused on developing gene therapies for hearing disorders, for $4.00 per share in cash plus a contingent value right, the companies announced Wednesday.
Decibel (DBTX) stock jumped ~78% in reaction while Regeneron (REGN) traded flat.
The non-tradable CVR valued at $3.50 per share in cash depends on the achievement of certain milestones related to the companyâs lead asset, DB-OTO, a gene therapy targeted at patients with hearing loss due to mutations of the otoferlin gene.
The transaction expected to close in Q3 2023 values Boston, Massachusetts-based Decibel (DBTX) at about $109M excluding the considerations for contingent value rights.
Per the terms, Regeneron (REGN) is expected to pay the initial amount of $4.00 per share for Decibel (DBTX) common stock at the closing of the deal.
Regeneron (REGN) and Decibel (DBTX) have partnered over the years for gene therapy programs targeted at congenital forms of hearing loss.

More on Regeneron 


Regeneron Pharmaceuticals Inc. (REGN) Q2 2023 Earnings Call Transcript
Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening
Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront
Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check
Regeneron gains after Q2 beat; FDA action on high-dose Eylea expected in Q3
Earnings data for Regeneron Pharmaceuticals